Table 2.

Summary of publications that have employed the AAV-vectorized expression of the hACE2 mouse model of SARS-CoV-2 infection.

AAV Serotype	Promoter	Dose (vg), Route of Administration, and Time Between AAV-hACE2 Transduction and SARS-CoV-2 Challenge	Strain of Mice	Interventions Tested	Reference
AAV9	CMV	1 × 1011 vg IT and challenged 2 weeks later	Male and female C57BL/6J (B6J), IFNAR−/− IRF3/7 double knockout	N/A	Israelow et al., 2020 [45]
AAV6.2FF	CASI	1 × 1011 vg IN and challenged 2 weeks later	Male and female BALB/c	DNA vaccine	Gary et al., 2021 [46]
AAV6 and AAV9	CMV	3 × 1011 vg IT (AAV6) and 1 × 1012 vg IP (AAV9), challenged 2 weeks later	C57BL/6J, BALB/c	Cocktail of chimeric anti-SARS-CoV-2 spike RBD monoclonal antibodies	Sun et al., 2021 [47]
Not provided	Not provided	1.6 × 1011 vg IN and challenged 2 weeks later	C57BL/6J Nlrp3−/−	NLRP3-specific inhibitor MCC950	Zeng et al., 2022 [48]
AAV9	Not provided	5 × 1011 vg IT and challenged 30 days later	BALB/c	Remdesivir metabolite GS-441524	Li et al., 2022 [49]
AAV8	CAG	4 × 1011 vg IT and 6 h later with 4 × 1011 vg IN; challenged 1 week later	C57BL/6, TLR7−/−, NOD2−/−, IFNAR−/−	N/A	Yang et al., 2022 [50]
AAV6, AAV9, AAVDJ	Not provided	2–6 × 1010 vg IN and challenged 10 days later	BALB/c	N/A	Glazkova et al., 2022 [51]
AAV6 and AAV9	CMV	3 × 1011 vg IT (AAV6) and 1 × 1012 vg IP (AAV9) and challenged 2 weeks later	BALB/c	Subunit vaccine UB-612	Wang et al., 2022 [52]
AAV6.2FF	CASI	1 × 1011 vg IN and challenged 10 days later	Male, female, old, and young C57BL/6 and BALB/c	N/A	Tailor et al., 2022 [53]
AAV6	CMV enhancer/beta-actin (CB) promoter	3 × 1011 vg IT; the interval between AAV and SARS-CoV-2 challenge was not provided	C57BL/6	Anti-PD-L1 antibody	Huang et al., 2023 [54]

vg = vector genome, IN = intranasal, IT = intratracheal, IP = intraperitoneal, N/A = not applicable.